Shin Nippon Biomedical Laboratories, Ltd. Stock OTC Markets

Equities

SBLOF

JP3379950003

Biotechnology & Medical Research

Delayed OTC Markets 11:58:04 2023-05-16 am EDT 5-day change 1st Jan Change
16.97 USD -.--% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. -.--% -.--%
Sales 2025 * 29.29B 187M Sales 2026 * 33.02B 211M Capitalization 54.04B 345M
Net income 2025 * 3.78B 24.13M Net income 2026 * 5.26B 33.65M EV / Sales 2025 * 2.62 x
Net Debt 2025 * 22.77B 146M Net Debt 2026 * 25.46B 163M EV / Sales 2026 * 2.41 x
P/E ratio 2025 *
14.3 x
P/E ratio 2026 *
10.3 x
Employees 1,341
Yield 2025 *
3.85%
Yield 2026 *
4.11%
Free-Float 46.34%
More Fundamentals * Assessed data
Dynamic Chart
Shin Nippon Biomedical Laboratories Included in FTSE Blossom Japan Sector Relative Index MT
Jefferies Cuts Shin Nippon Biomedical Laboratories' EPS Estimates by 37% on 'Disappointing' Guidance, Weak Translational Research Unit MT
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 1,500 Yen From 2,800 Yen MT
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval MT
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024 CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers. CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024 CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals MT
Sector Update: Health Care Stocks Higher Premarket Monday MT
More news
3 years
16.97
Extreme 16.97
16.97
5 years
16.97
Extreme 16.97
16.97
10 years
16.97
Extreme 16.97
16.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 81-08-31
Director of Finance/CFO 55 02-04-30
Compliance Officer - 84-03-31
Members of the board TitleAgeSince
Director/Board Member 38 17-03-31
Sales & Marketing 64 02-10-31
Chief Operating Officer 60 02-11-30
More insiders
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
1,298 JPY
Average target price
1,450 JPY
Spread / Average Target
+11.71%
Consensus